Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics, Inc. (JSPR)
:JSPR
JSPR Stock Chart & Stats
$2.18
-$10.02(-56.58%)
At close: 4:00 PM EST
$2.18
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$2.16 - $26.05
Previous CloseN/A
Volume4.28M
Average Volume (3M)471.34K
Market Cap
$63.67M
Enterprise Value$47.75M
Total Cash (Recent Filing)$39.51M
Total Debt (Recent Filing)$2.15M
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Nov 06, 2025EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding27,924,040
10 Day Avg. Volume399,457
30 Day Avg. Volume471,338
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue40.67
Enterprise Value/Gross Profit-97.25
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$12.60Price Target Upside477.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst believes briquilimab has a highly competitive profile at an attractive valuation, hence the Buy recommendation remains.
Clinical DataUpdated CSU data from Ph1b/2a BEACON study showed impressive efficacy with 89% CR for the 240mg and 360mg single dose cohorts.
Efficacy And SafetyThe SPOTLIGHT study's 180 mg cohort showed a 92% complete response rate, a 100% clinical response, and a rapid onset of action without any safety concerns, further supporting briquilimab's safety and efficacy profile.
Bears Say
Competition DelayThe expected start for the Ph2b CSU study has now been pushed out to mid-'26, placing Jasper ~18-24 months behind the competition.
Manufacturing IssuesStrong OLE Data But Further Delays and Cash Crunch From Drug Lot Issues Create Uncertainty; Downgrading to Market Perform.
Product Lot VariabilitySome cohorts in BEACON were impacted by an inactive drug product lot, confounding the results and requiring re-dosing and additional patient enrollment.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics, Inc.’s price range in the past 12 months?
Jasper Therapeutics, Inc. lowest stock price was $2.16 and its highest was $26.05 in the past 12 months.
What is Jasper Therapeutics, Inc.’s market cap?
Jasper Therapeutics, Inc.’s market cap is $63.67M.
When is Jasper Therapeutics, Inc.’s upcoming earnings report date?
Jasper Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 5 days.
How were Jasper Therapeutics, Inc.’s earnings last quarter?
Jasper Therapeutics, Inc. released its earnings results on Aug 13, 2025. The company reported -$1.74 earnings per share for the quarter, missing the consensus estimate of -$1.326 by -$0.414.
Is Jasper Therapeutics, Inc. overvalued?
According to Wall Street analysts Jasper Therapeutics, Inc.’s price is currently Undervalued.
Does Jasper Therapeutics, Inc. pay dividends?
Jasper Therapeutics, Inc. does not currently pay dividends.
What is Jasper Therapeutics, Inc.’s EPS estimate?
Jasper Therapeutics, Inc.’s EPS estimate is -1.22.
How many shares outstanding does Jasper Therapeutics, Inc. have?
Jasper Therapeutics, Inc. has 27,924,040 shares outstanding.
What happened to Jasper Therapeutics, Inc.’s price movement after its last earnings report?
Jasper Therapeutics, Inc. reported an EPS of -$1.74 in its last earnings report, missing expectations of -$1.326. Following the earnings report the stock price went up 2.02%.
Which hedge fund is a major shareholder of Jasper Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JSPR
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.60 (477.98% Upside)
$12.60 (477.98% Upside)
Blogger Sentiment
Bullish
JSPR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 256.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $347.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.23%
12-Months-Change
Fundamentals
Return on Equity
-146.87%
Trailing 12-Months
Asset Growth
-59.21%
Trailing 12-Months
Company Description
Jasper Therapeutics, Inc.
Jasper Therapeutics (JSPR) is a biotechnology company focused on the development of innovative therapies for diseases of the hematopoietic system, including immunology and oncology conditions. The company is dedicated to advancing its pipeline of novel therapies aimed at improving patient outcomes by targeting the root causes of these diseases. Jasper Therapeutics' lead product candidate is designed to improve the success and safety of hematopoietic cell transplants, which are critical for treating a variety of life-threatening diseases.
JSPR Stock 12 Month Forecast
Average Price Target
$12.60
▲(477.98% Upside)
Technical Analysis
Ownership Overview
1.35% Insiders
4.63% Mutual Funds
27.57% Other Institutional Investors
62.18% Public Companies and
Individual Investors